The son of a pharmaceuticals distributor, Dilip Shanghvi borrowed $200 from his father to start Sun Pharmaceutical Industries in 1983 to make psychiatric drugs. The company is India's most valuable listed pharma outfit and gets two-thirds of its $4.5 billion annual revenue from overseas markets. He grew Sun through a series of acquisitions, the biggest of which was the 2014 purchase of scandal-tainted rival Ranbaxy Laboratories for $4 billion. Autoparts billionaire Vivek Chaand Sehgal sits on Sun's board.